OBJECTIVE: To describe and report the feasibility of a novel field telephonic strategy to elicit explicit informed consent in prehospital trials for conditions in which patients retain decision-making capacity. METHODS: In a pilot prehospital neuroprotective stroke therapy trial, ambulances carried written informed consent forms and dedicated trial cellular phones permitting rapid connection to on call physician-investigators. The physician-investigator discussed the trial with the consent provider [patient if competent, on scene legally authorized representative (LAR) if patient not competent] by phone, while paramedics carried out prehospital care duties unimpeded. RESULTS: 32 patients met consent elicitation criteria. 20 (63%) were enrolled. The most frequent reasons for non-enrollment were: patient not competent and no available on-scene LAR-5; patient/LAR declined participation-4. Among enrollees, 15 (75%) were competent and self-enrolled; 5 (25%) were not competent and were enrolled by LAR family members. Site of consent initiation was: patient home-15 (74 = 5%), work-2(10)%, other-3(15)%. Consent was elicited via cell phone in 11 (55%) and site landline in 9 (45%). Compared with patients enrolled in prior studies employing standard in-hospital consent, prehospital consent procedures reduced time from paramedic arrival on-scene to start of study agent (26 vs 139 mins, p < 0.0001), and did not prolong the on-scene to ED arrival time (37 vs 34 min, p = 0.50). No patient/family withdrew consent during the 3-month follow-up period. CONCLUSION: Physician phone elicitation of prehospital research consent from individuals with retained competency or on-scene legally authorized representatives is feasible, permits rapid patient study entry, and does not delay field transport times.
OBJECTIVE: To describe and report the feasibility of a novel field telephonic strategy to elicit explicit informed consent in prehospital trials for conditions in which patients retain decision-making capacity. METHODS: In a pilot prehospital neuroprotective stroke therapy trial, ambulances carried written informed consent forms and dedicated trial cellular phones permitting rapid connection to on call physician-investigators. The physician-investigator discussed the trial with the consent provider [patient if competent, on scene legally authorized representative (LAR) if patient not competent] by phone, while paramedics carried out prehospital care duties unimpeded. RESULTS: 32 patients met consent elicitation criteria. 20 (63%) were enrolled. The most frequent reasons for non-enrollment were: patient not competent and no available on-scene LAR-5; patient/LAR declined participation-4. Among enrollees, 15 (75%) were competent and self-enrolled; 5 (25%) were not competent and were enrolled by LAR family members. Site of consent initiation was: patient home-15 (74 = 5%), work-2(10)%, other-3(15)%. Consent was elicited via cell phone in 11 (55%) and site landline in 9 (45%). Compared with patients enrolled in prior studies employing standard in-hospital consent, prehospital consent procedures reduced time from paramedic arrival on-scene to start of study agent (26 vs 139 mins, p < 0.0001), and did not prolong the on-scene to ED arrival time (37 vs 34 min, p = 0.50). No patient/family withdrew consent during the 3-month follow-up period. CONCLUSION: Physician phone elicitation of prehospital research consent from individuals with retained competency or on-scene legally authorized representatives is feasible, permits rapid patient study entry, and does not delay field transport times.
Authors: Nerses Sanossian; Sidney Starkman; Mark Eckstein; Samuel Stratton; Frank Pratt; Robin Conwit; Jeffrey L Saver Journal: Cerebrovasc Dis Date: 2010-07-28 Impact factor: 2.762
Authors: Duika L Burges Watson; Randy Sanoff; Joan E Mackintosh; Jeffrey L Saver; Gary A Ford; Christopher Price; Sidney Starkman; Marc Eckstein; Robin Conwit; Anna Grace; Madeleine J Murtagh Journal: Ann Emerg Med Date: 2012-03-03 Impact factor: 5.721
Authors: Jeffrey L Saver; Sidney Starkman; Marc Eckstein; Samuel Stratton; Frank Pratt; Scott Hamilton; Robin Conwit; David S Liebeskind; Gene Sung; Nerses Sanossian Journal: Int J Stroke Date: 2014-02 Impact factor: 5.266
Authors: Nerses Sanossian; Sidney Starkman; David S Liebeskind; Latisha K Ali; Lucas Restrepo; Scott Hamilton; Robin Conwit; Jeffrey L Saver Journal: Cerebrovasc Dis Date: 2009-10-16 Impact factor: 2.762